Have a feature idea you'd love to see implemented?
Let us know!
EWTX Edgewise Therapeutics Inc
Price (delayed)
$31.98
Market cap
$3.03B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.5
Enterprise value
$2.99B
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need.
Highlights
Edgewise Therapeutics's debt has decreased by 20% YoY and by 11% from the previous quarter
Edgewise Therapeutics's equity has soared by 68% YoY but it has decreased by 4.2% from the previous quarter
The quick ratio has grown by 47% YoY but it has contracted by 13% from the previous quarter
The net income is down by 39% year-on-year and by 7% since the previous quarter
Key stats
What are the main financial stats of EWTX
Market
Valuations
Earnings
Shares outstanding
94.69M
Market cap
$3.03B
Enterprise value
$2.99B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.13
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$124.29M
EBITDA
-$122.1M
Free cash flow
-$110.1M
Per share
Balance sheet
Liquidity
EPS
-$1.5
Free cash flow per share
-$1.17
Book value per share
$5.21
Revenue per share
$0
TBVPS
$5.45
Total assets
$511.28M
Total liabilities
$22.41M
Debt
$4.44M
Equity
$488.88M
Working capital
$480.48M
Debt to equity
0.01
Current ratio
26.35
Quick ratio
25.98
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-25.7%
Return on equity
-26.8%
Return on invested capital
-29.5%
Return on capital employed
-25.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EWTX stock price
How has the Edgewise Therapeutics stock price performed over time
Intraday
0.09%
1 week
-2.71%
1 month
-8.24%
1 year
404.42%
YTD
192.32%
QTD
19.82%
Financial performance
How have Edgewise Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$147.15M
Net income
-$124.29M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 43% year-on-year and by 8% since the previous quarter
The net income is down by 39% year-on-year and by 7% since the previous quarter
Growth
What is Edgewise Therapeutics's growth rate over time
Valuation
What is Edgewise Therapeutics stock price valuation
P/E
N/A
P/B
6.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 6% YoY but it rose by 3.2% QoQ
The P/B is 80% more than the last 4 quarters average of 3.4
Edgewise Therapeutics's equity has soared by 68% YoY but it has decreased by 4.2% from the previous quarter
Efficiency
How efficient is Edgewise Therapeutics business performance
EWTX's ROIC is up by 4.5% QoQ and by 2.6% YoY
EWTX's ROA is up by 3.7% since the previous quarter and by 2.7% year-on-year
Edgewise Therapeutics's ROE has increased by 4.3% from the previous quarter and by 4.3% YoY
Dividends
What is EWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EWTX.
Financial health
How did Edgewise Therapeutics financials performed over time
The total assets has soared by 64% YoY but it has contracted by 3.8% from the previous quarter
The quick ratio has grown by 47% YoY but it has contracted by 13% from the previous quarter
Edgewise Therapeutics's debt is 99% less than its equity
Edgewise Therapeutics's equity has soared by 68% YoY but it has decreased by 4.2% from the previous quarter
Edgewise Therapeutics's debt to equity has shrunk by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.